BGI wins partial lifting of Illumina injunction

Beijing-based BGI Genomics can continue to develop its DNA sequencing technology pending an appeal in a patent dispute with Illumina, a US federal court has ruled.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Illumina prevails against BGI at English High Court

21 January 2021 Illumina has secured a victory in its patent dispute with Chinese genome sequencing company BGI at the English High Court, which ruled that four of its patents had been infringed.

Americas

Illumina to acquire Jeff Bezos-backed cancer testing company

23 September 2020 Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.

Americas

Illumina secures injunction against BGI

18 June 2020 Genetic sequencing company Illumina has obtained a preliminary injunction against its China-based rival BGI.